Patient code | IgG antibody titer | IgA antibody titer | IgM antibody titer | VEGF/VEGFR2 blockade (%) |
---|
Pre-vaccination | Re-immunization phase | Pre-vaccination | Re-immunization phase | Pre-vaccination | Re-immunization phase | Pre-vaccination | Re-immunization phase |
---|
Week 0 | Sample A | Sample B | Week 0 | Sample A | Sample B | Week 0 | Sample A | Sample B | Week 0 | Sample A | Sample B |
---|
CH08 | 4 | 36 | 31 | 49 | 70 | 71 | 1183 | 1035 | 1101 | 11.2 | 18.7 | 11.9 |
JL12 | 26 | 700*
| 770*
| 49 | 93 | 56 | 298 | 528 | 604*
| 6.92 | 7.5 | 15.2*
|
CQ13 | 4 | 505*
| 582*
| 335 | 286 | 305 | 1655 | 2090 | 2198†
| 10.8 | 29.4*
| 24.5*
|
CH19 | 4 | 232*
| 244*
| 49 | 59 | 68 | 1180 | 1462 | 1978†
| 11.5 | 16.1 | 31.5*,#
|
CH20 | 1 | 374*
| 339*
| 110 | 94 | 62 | 963 | 629 | 675 | 4.6 | 12.1*
| 16.7*
|
CH27 | 8 | 207*
| 236*
| 268 | 472 | 319 | 1947 | 3422 | 3732†
| 14.2 | 31.1*
| 29.9*
|
JL29 | 118 | 589*
| 795*,†
| 87 | 124 | 144 | 707 | 438 | 557†
| 11.2 | 7.2 | 20.8#
|
JL30 | 1 | 17 | 17 | 69 | 72 | 75 | 886 | 663 | 688 | 14 | 19 | 18 |
CH33 | 133 | 1655*
| 1697*
| 111 | 676*
| 530*
| 2591 | 341140*
| 3859811*,†
| 8.7 | 27.2*
| 28.9*
|
JL42 | 41 | 40 | 56 | 70 | 73 | 96 | 1788 | 1374 | 2426†
| 20 | 17 | 27#
|
CH45 | 0 | 4474*
| 3825*
| 48 | 80 | 84 | 543 | 4108*
| 4995*,†
| 7.6 | 27.4*
| 23*
|
JL49 | 463 | 947*
| 1110*,†
| 70 | 155*
| 125 | 509 | 1114*
| 1027*
| 16.3 | 27.5 | 34.1*
|
- Sample “A”: is the value for the sample taken just before the re-immunization; Sample “B”: is the value for the sample acquired 7–10 days after the taking of the sample “A”. [*]: sample meets the positivity criteria for specific-IgG (using formulas A and B), IgA or IgM antibodies (using formula A) or VEGF/VEGFR2 blockade (using formula D). (†): sample meets the criterion of increase for antibody titer: sample “B” - sample “A” ≥ 1/100. (#): sample meets the criterion of increase for VEGF/VEGFR2 blockade: sample “B” - sample “A” ≥ 10%. Patients: CH08 (sample A taken at week 55; sample B taken at week 56); JL12 (sample A taken at week 53; sample B taken at week 54); CQ13 (sample A taken at week 48; sample B taken at week 49); CH19 (sample A taken at week 47; sample B taken at week 48); CH20 (sample A taken at week 50; sample B taken at week 51); CH27 (sample A taken at week 45; sample B taken at week 46); JL29 (sample A taken at week 48; sample B taken at week 49); JL30 (sample A taken at week 52; sample B taken at week 53); CH33 (sample A taken at week 48; sample B taken at week 49); JL42 (sample A taken at week 49; sample B taken at week 50); CH45 (sample A taken at week 48; sample B taken at week 49); JL49 (sample A taken at week 44; sample B taken at week 45)